SynaptixBio’s collaboration with leading global drug researcher Evotec featured in European Biotechnology Magazine
- Jul 12
Dan Williams and Amy Sheridan-Hill, whose son Frankie suffers from H-ABC, interviewed for the Evening Standard.
- Jun 11
In a major article, Dan Williams considers how to overcome obstacles in rare disease treatment
- Jun 11
Leading biotech appoints senior industry figure as Chief Medical Officer to define clinical strategy and oversee trials
- Apr 30
Bioscience Today features major Dan Williams article about collaboration driving rare disease drug development
- Apr 30
Dan Williams says Big Pharma could help accelerate market introduction for rare disease drugs
- Apr 30
SynaptixBio awarded second FDA Orphan Drug Designation to boost search for rare disease therapies
- Dec 23, 2023
BBC features TUBB4A leukodystrophy case study – Dan Williams contribution highlights lack of widespread awareness of rare diseases
- Dec 23, 2023
Dan Williams interviewed for prestigious journal - Major International Clinical Trials feature showcases SynaptixBio story
- Dec 23, 2023
Leading biotech firm welcomes new NHS rapid diagnostic service for rare diseases, but says wider newborn screening is key
- Dec 23, 2023
SynaptixBio awarded prestigious Innovate UK grant to expand search for rare disease therapies
- Apr 28, 2023
Oxford biotech firm secures £13.2m to develop first treatment for rare, incurable, deadly disease.
- Feb 10, 2023
British biotech firm secures FDA rare paediatric disease designation
- Jan 8, 2023
Children with undiagnosed conditions urged to get checked for rare, incurable and deadly disease